CoChat

Psychoanalytically informed MDMA-assisted therapy for pathological narcissism: a novel theoretical approach

Open access
Albert, Alexa E., Back, Anthony L. · 2025 · Frontiers in Psychiatry

The DOI matches its Crossref record; 180 of the 186 references it cites were found in a registry or an index, and 5 are not checked yet; 101 of the 225 sources its claims cite were checked for support.

Abstract

Pathological narcissism (PN) is a complex, treatment-resistant disorder characterized by unstable self-esteem that fluctuates between grandiosity and vulnerability, complicating the formation of a stable self-image. With few empirically supported therapies, treatment has traditionally relied on long-term psychoanalytic approaches, but these often face high attrition. Recent research suggests a potential therapeutic synergy between psychedelics and psychoanalytic therapy, offering a novel approach to addressing entrenched personality structures. Studies on MDMA (3,4-methylenedioxymethamphetamine), a compound known for enhancing empathy, trust, and social interactions, demonstrate potential to reopen critical periods for social learning in adults, offering the possibility of therapeutic benefits for conditions with core issues in relatedness, such as PN. MDMA promotes psychological flexibility and openness, allowing for deeper self-exploration and strengthening the observing ego, considered in psychoanalytic therapy to be an essential component for recognizing and modifying maladaptive patterns. By reducing fear-based avoidance in the brain, MDMA facilitates access to unconscious emotions, helping individuals process overwhelming feelings linked to early relational trauma commonly seen in PN. Additionally, MDMA’s capacity to enhance compassion and empathy can fortify the therapeutic alliance, increasing its potential to facilitate relational change. This paper presents an MDMA-assisted therapy (MDMA-AT) tailored for narcissistic patients which is currently being conducted as an investigator-initiated trial (IIT). It explores the model’s theoretical foundations, mechanisms of change, treatment framework, and clinical challenges. Combining MDMA with an evidence-based depth therapy like psychoanalytic psychotherapy may offer an innovative treatment for conditions associated with attachment and developmental trauma, particularly personality disorders. While the role of psychotherapy in psychedelic treatments remains a topic of debate, with some proposing psychedelics be administered without psychotherapy, we assert that individuals with early relational trauma stand the most to gain from an integrated psychedelic-assisted therapy (PAT) model, where MDMA enhances the therapeutic alliance and emotional openness while psychoanalytic interventions provide the structure for lasting change. Copyright © 2025 Albert and Back.

Verified 2026-11-19 · 5 references not checked yet

Overview

CoChat Summary

## TL;DR

This paper is a hypothesis/theoretical article proposing a psychoanalytically informed MDMA-assisted therapy (MDMA-AT) for pathological narcissism (PN), and it situates the model in an ongoing investigator-initiated pilot study. The authors argue that MDMA’s prosocial and fear-reducing effects may complement psychoanalytic psychotherapy by improving reflective functioning, emotion regulation, agency, and the therapeutic alliance.

## Key findings

  • The paper frames PN as a treatment-resistant condition with high dropout in conventional long-term psychoanalytic treatment and no strong empirical evidence for pharmacotherapy; it notes dropout rates of 63–64% in psychodynamic therapies.
  • It reports that PN prevalence estimates reach up to 6.2% in the U.S. general population, with higher rates among men (7.7%) than women (4.8%), and that prevalence in clinical populations may be up to 20%.
  • The authors cite prior psychedelic findings relevant to personality change, including one study in which ayahuasca was associated with modest reductions in entitlement and increases in leadership authority up to three months post-retreat, though effect sizes were small and results mixed.
  • The paper states that the proposed MDMA-AT is being evaluated in an investigator-initiated pilot study titled “A Pilot Study of MDMA-Assisted Therapy for the Treatment of Pathological Narcissism” (NCT06565494), and that this will be the first known clinical trial to integrate psychoanalytic techniques with psychedelic medicine.

## Methods

  • This is a theoretical/hypothesis paper that proposes a treatment model rather than reporting completed efficacy results; it is built from literature on PN, psychoanalytic therapy, and MDMA/PAT.
  • The paper describes an ongoing investigator-initiated pilot study at the University of Washington IRB with participants aged 18–64 who meet DSM-5 Section III criteria for PN or narcissistic personality disorder and are already in outpatient psychotherapy.
  • The pilot protocol uses a three-phase PAT structure (Preparation, Medicine, Integration), with three Preparation sessions (60–90 minutes each), three MDMA sessions spaced about four weeks apart, and three Integration sessions after each MDMA session; primary outcome is the Brief Pathological Narcissism Inventory (B-PNI), with safety monitoring including C-SSRS and SPSI.

## Limitations

  • The paper explicitly notes that the combined potential of psychoanalytic therapy and MDMA-assisted therapy for PN remains unexplored, and that the pilot study is intended to provide only preliminary insights into safety and efficacy.
  • It states that the field lacks clinical trials exploring psychoanalytic approaches to PAT, so the model is largely theoretical at this stage.
  • Evident from the text: the article does not report completed trial outcomes, so its claims about benefit are hypothetical and not yet empirically validated in PN.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3389/fpsyt.2025.1529427

Cites

180 of 186 references verified1 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Schema of treatment model phases.
Figure 1 Schema of treatment model phases.CC BY · PubMed Central

Verification

Claims the paper makes

73 Valid · 8 Not valid · 56 Not checked · 32 Own results and interpretations

58 more claims · 19 with their cited sources checked

Create a free account to see all 169 claims and to verify the 7 references still open.

See all claims — free account
  • Probably not a substantial claim. 35
  • It may state two separate claims as one. 84

Create a free account to see these claims.

Citations

Cites

Research works printed but not linked: 11

  1. Atalay AN. Psychedelic therapy for personality disorders. Psychedelic Support. 2024 Nov 13. Available at: https://psychedelic.support/resources/psychedelic-therapy-for-personality-disorders/ [Accessed February 8, 2025].
  2. Gasser P. Psycholytic therapy with MDMA and LSD in Switzerland. MAPS Bull. (1995) 5(3): 3– 7. Available from: https://maps.org/news-letters/v05n3/05319gas.html (Accessed February 8, 2025).
  3. Winnicott DW. Ego distortion in terms of true and false self. In: The maturational processes and the facilitating environment. International Universities Press, New York (1965). p. 140–57.
  4. Diamond D Yeomans FE Stern BL Kernberg OF. Treating pathological narcissism with transference-focused psychotherapy. New York: Guilford Press (2021).
  5. Choi-Kain LW Simonsen S Euler S. A mentalizing approach for narcissistic personality disorder: Moving toward integrated treatment. Am J Psychother. (2022) 75: 38– 43. doi: 10.1176/appi.psychotherapy.20210017 35016552 · DOI · Paper page
  6. Shepherd M. Revisiting the repetition compulsion: Danger and survival in early mental functioning. Mod Psychoanal. (2014) 39(1): 56– 69.
  7. Frosch J. From grievance to grief: nnarcissism and the inability to mourn. Can J Psychoanal. (2014) 22(2): 259–75.
  8. Ronningstam E. NPD Basic: A brief overview of identifying, diagnosing, and treating Narcissistic Personality Disorder. 4th ed. Belmont, MA: McLean Hospital, Harvard Medical School (2021).
  9. Diamond D Yeomans FE Stern BL Kernberg OF. Treating pathological narcissism with transference-focused psychotherapy. New York: The Guilford Press (2022). p. 192.
  10. First MB Skodol AE Bender DS Oldham JM. Module III: Structured Clinical Interview for Personality Disorders (Including Personality Disorder-Trait Specified). In: First MB Skodol AE Bender DS Oldham JM, editors. Structured Clinical Interview for the DSM-5 Alternative Model for Personality Disorders (SCID-AMPD). American Psychiatric Publishing, Arlington VA (2018).
  11. Movahed Rad P. Psychedelics could pose risks for people with personality disorders, study finds. Sci Alert 2024 Apr 15. https://www.sciencealert.com/psychedelics-could-pose-risks-for-people-with-personality-disorders-study-finds [Accessed February 8, 2025].

Cited by

See all 6

Metadata

Authors
Albert, A. E., & Back, A. L.
Affiliations
University of Washington (US)
Corresponding author
Albert, Alexa E.
Venue
Frontiers in Psychiatry
Published
2025-04-02
Volume
16
Pages
1529427-1529427
ISSN
1664-0640 (ISSN-L)
OpenAlex
W4409083076
Cited by
6
References
183
Citations by year
2026: 4 · 2025: 2
FWCI
7.09
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Psychiatry (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
  • Social Sciences › Psychology › Clinical Psychology › Psychoanalysis and Psychopathology Research
  • Social Sciences › Psychology › Clinical Psychology › Personality Disorders and Psychopathology
Keywords
pathological narcissism, MDMA-assisted psychotherapy, psychedelic-assisted psychotherapy, psychoanalytic psychotherapy, early relational trauma, attachment trauma, therapeutic relationship, mechanisms of change, empathy, self-esteem, personality disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.